Table 2 Demographic and clinic data for the subset of patients treated with IAS (n = 39) and had at least once follow up comparing those who failed treatment with IAS and restarted a systemic medication with those who did not fail. RF, CCP, and B27 were left off due to the small number of positives. All were non-significant. *p > 0.05 when psoriatic, ERA and undifferentiated JIA were excluded

Total (n, %)

Failed n, %

No fail n, %

p-value

All

39, 100%

19, 49%

20, 51%

Sex

Male

9, 23%

5, 26%

4, 20%

0.72

Female

30, 77%

14, 74%

16, 80%

Age at Diagnosis (years)

7.28 (4.59)

6.7 (3.8)

7.8 (5.2)

0.48

JIA subtype

Oligoarticular

22, 56%

10, 53%

12, 60%

0.63*

Polyarticular

13, 33%

7, 37%

6, 30%

Psoriatic

3, 8%

1, 5%

2, 10%

ERA

1, 3%

1, 5%

0, 0%

Undifferentiated

0, 0%

0, 0%

0, 0%

ANA

Negative

19, 49%

10, 53%

9, 45%

0.63

Positive

20, 51%

9, 47%

11, 55%

Uveitis

No

32, 82%

14, 74%

18, 90%

0.24

Yes

7, 18%

5, 26%

2, 10%

Methotrexate

No

1, 3%

0, 0%

1, 5%

1

Yes

38, 97%

19, 100%

19, 95%

Biologic

No

17, 44%

4, 21%

13, 65%

< 0.01

Yes

22, 56%

15, 79%

7, 35%

12 month follow up

Total (n, %)

Failed n, %

No fail n, %

p-value

All

30, 100%

21, 70%

9, 30%

Sex

Male

5, 17%

4, 19%

1, 11%

1

Female

25, 83%

17, 81%

8, 89%

Age at Diagnosis (years)

7.1 (4.5)

7.7 (4.2)

5.6 (5.1)

0.29

JIA subtype

Oligoarticular

16, 53%

11, 52%

5, 56%

1*

Polyarticular

11, 37%

7, 33%

4, 44%

Psoriatic

2, 7%

2, 10%

0, 0%

ERA

1, 3%

1, 5%

0, 0%

Undifferentiated

0, 0%

0, 0%

0, 0%

ANA

Negative

18, 60%

12, 57%

6, 67%

0.7

Positive

12, 40%

9, 43%

3, 33%

Uveitis

No

25, 83%

17, 81%

8, 89%

1

Yes

5, 17%

4, 19%

1, 11%

Methotrexate

No

1, 3%

0, 0%

1, 11%

0.3

Yes

29, 97%

21, 100%

8, 89%

Biologic

No

10, 33%

4, 19%

6, 67%

< 0.05

Yes

20, 67%

17, 81%

3, 33%